国际放射医学核医学杂志
國際放射醫學覈醫學雜誌
국제방사의학핵의학잡지
INTERNATIONAL JOURNAL OF RADIATION MEDICINE AND NUCLEAR MEDICINE
2013年
3期
150-152
,共3页
癌,非小细胞肺%辐射增敏药%放射疗法%塞来昔布%模型,动物
癌,非小細胞肺%輻射增敏藥%放射療法%塞來昔佈%模型,動物
암,비소세포폐%복사증민약%방사요법%새래석포%모형,동물
Carcinoma,non-small-cell lung%Radiation-sensitizing agents%Radiotherapy%Celecoxib
目的 建立裸鼠非小细胞肺癌H460细胞动物模型,观察环氧化酶2选择性抑制剂塞来昔布对H460放疗的增敏作用,并对其作用机理进行初步探讨.方法 将40只荷瘤鼠用完全随机法分成4组,分别为空白对照组、放疗组、塞来昔布组、塞来昔布+放疗组,每组10只.采用灌肠法给予塞来昔布16 mg·kg-1·d-1,给药2h后进行放疗,放疗分割剂量为5 Gy/次,2次/周,4周后处死所有荷瘤鼠,解剖瘤块称重.采用免疫组化方法分析毛细血管扩张性共济失调症突变蛋白(ATM)和表皮生长因子受体(EGFR)表达的变化.结果 空白对照组、塞来昔布组、放疗组、塞来昔布+放疗组肿瘤瘤重分别为(133.62 ± 12.37)、(130.37 ±12.59)、(81.17±8.29)、(35.51 ±4.23)mg,塞来昔布+放疗组与放疗组比较差异有统计学意义(t=5.41,P＜0.01).塞来昔布+放疗组的ATM和EGFR表达水平明显降低,与放疗组比较差异有统计学意义(t=4.23和3.17,P均＜0.01).结论 塞来昔布可能通过降低ATM和EGFR的表达水平,增强H460细胞的放疗敏感性,将来可能具有较好的临床应用价值.
目的 建立裸鼠非小細胞肺癌H460細胞動物模型,觀察環氧化酶2選擇性抑製劑塞來昔佈對H460放療的增敏作用,併對其作用機理進行初步探討.方法 將40隻荷瘤鼠用完全隨機法分成4組,分彆為空白對照組、放療組、塞來昔佈組、塞來昔佈+放療組,每組10隻.採用灌腸法給予塞來昔佈16 mg·kg-1·d-1,給藥2h後進行放療,放療分割劑量為5 Gy/次,2次/週,4週後處死所有荷瘤鼠,解剖瘤塊稱重.採用免疫組化方法分析毛細血管擴張性共濟失調癥突變蛋白(ATM)和錶皮生長因子受體(EGFR)錶達的變化.結果 空白對照組、塞來昔佈組、放療組、塞來昔佈+放療組腫瘤瘤重分彆為(133.62 ± 12.37)、(130.37 ±12.59)、(81.17±8.29)、(35.51 ±4.23)mg,塞來昔佈+放療組與放療組比較差異有統計學意義(t=5.41,P＜0.01).塞來昔佈+放療組的ATM和EGFR錶達水平明顯降低,與放療組比較差異有統計學意義(t=4.23和3.17,P均＜0.01).結論 塞來昔佈可能通過降低ATM和EGFR的錶達水平,增彊H460細胞的放療敏感性,將來可能具有較好的臨床應用價值.
목적 건립라서비소세포폐암H460세포동물모형,관찰배양화매2선택성억제제새래석포대H460방료적증민작용,병대기작용궤리진행초보탐토.방법 장40지하류서용완전수궤법분성4조,분별위공백대조조、방료조、새래석포조、새래석포+방료조,매조10지.채용관장법급여새래석포16 mg·kg-1·d-1,급약2h후진행방료,방료분할제량위5 Gy/차,2차/주,4주후처사소유하류서,해부류괴칭중.채용면역조화방법분석모세혈관확장성공제실조증돌변단백(ATM)화표피생장인자수체(EGFR)표체적변화.결과 공백대조조、새래석포조、방료조、새래석포+방료조종류류중분별위(133.62 ± 12.37)、(130.37 ±12.59)、(81.17±8.29)、(35.51 ±4.23)mg,새래석포+방료조여방료조비교차이유통계학의의(t=5.41,P＜0.01).새래석포+방료조적ATM화EGFR표체수평명현강저,여방료조비교차이유통계학의의(t=4.23화3.17,P균＜0.01).결론 새래석포가능통과강저ATM화EGFR적표체수평,증강H460세포적방료민감성,장래가능구유교호적림상응용개치.
Objective To establish the nude mice model of non-small cell lung cancer (NSCLC)H460 cell to investigate the combined effects of radiotherapy and celecoxib.Methods Athymic mice bearing H460 were randomly divided into 4 groups:control,radiotherapy,celecoxib and radiotherapy plus celecoxib group.The administration dose of celecoxib was 16 mg·kg-1·d-1.The mice were treated with radiotherapy 2 hours after administration and the fractionated dose was 5 Gy,2 fractions per week.Mice were killed to detect tumor weight 4 weeks after treatment.The expression levels of ataxia telangiectasis mutated (ATM)and epidermal growth factor receptor (EGFR)in tumor tissues were detected by immune-histochmical method.Results The tumor weight in control,radiotherapy,celecoxib and radiotherapy plus celecoxib group were(133.62±12.37),(130.37 ±12.59),(81.17 ±8.29) and (35.51 ±4.23) mg respectively.There was significant difference between the radiotherapy plus celeeoxib group and the radiotherapy group (t=5.41,P＜0.01).The expression levels of ATM and EGFR in the radiotherapy plus celecoxib group were significantly lower than that in radiotherapy group (t=4.23 and 3.17,both P＜0.01).Conclusions Celecoxib promotes radiotherapeutic sensitivity of H460 by down-regulating the expression levels of ATM and EGFR.Celecoxib may presents potency in curing human lung cancer.
